ABS 013: The Ovarian Response to Platelet-Rich Plasma Treatment in Infertile Women Before Oocyte Retrieval

Caila Menichella ¹

¹ University of South Florida

The Van Wickle Journal (2026) Volume 2, ABS013

Introduction: Platelet-rich plasma (PRP) has become an advanced therapy used in many medical specialties and has recently become a subject of interest in reproductive medicine, specifically focusing on infertility. Impaired ovarian health issues including maternal aging, decreased ovarian reserve (DOR), and premature ovarian insufficiency (POI) are major contributors to reduced fertility. PRP performed on the ovary has been proposed as a regenerative therapy to reverse ovarian aging and enhance the endocrine function for an increase in the dormant follicle count. This systematic review analyzes the effect of intra-ovarian platelet-rich plasma therapy in infertile women administered before oocyte retrieval, with a focus on the quality and quantity of mature oocytes. A systematic search of the literature was conducted to evaluate the efficacy of intra-ovarian platelet-rich plasma injections on ovarian reserve markers including anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and antral follicle count (AFC). A search was performed using scholarly databases including PubMed and ScienceDirect published between 2021 and 2025. The search incorporated keywords such as platelet-rich plasma, infertility, poor ovarian response, intra-ovarian, and diminished ovarian reserve. Studies were eligible for inclusion if they evaluated intra-ovarian PRP in infertile women and reported ovarian reserve markers before and after treatment. A total of 51 studies comprising 3,545 women were included across the analyzed review. Intra-ovarian PRP injections were associated with significant improvements in ovarian reserve markers within 1-3 months after treatment, including increased AMH and AFC levels along with decreased FSH. Reproductive success outcomes were observed, including increased total and mature (MII) oocyte retrieval following treatment. Furthermore, higher embryo formation rates and enhanced cleavage and blastocyst-stage embryo development were reported. After administration, 22% of women achieved a clinical pregnancy while 5% experienced natural conception. Intra-ovarian PRP has shown potential to improve reproductive outcomes in women with impaired ovarian function.


Methods: A systematic search of the literature was conducted to evaluate the efficacy of intra-ovarian platelet-rich plasma injections on ovarian reserve markers including anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and antral follicle count (AFC). A search was performed using scholarly databases including PubMed and ScienceDirect published between 2021 and 2025. The search incorporated keywords such as platelet-rich plasma, infertility, poor ovarian response, intra-ovarian, and diminished ovarian reserve. Studies were eligible for inclusion if they evaluated intra-ovarian PRP in infertile women and reported ovarian reserve markers before and after treatment.

Results: A total of 51 studies comprising 3,545 women were included across the analyzed review. Intra-ovarian PRP injections were associated with significant improvements in ovarian reserve markers within 1-3 months after treatment, including increased AMH and AFC levels along with decreased FSH. Reproductive success outcomes were observed, including increased total and mature (MII) oocyte retrieval following treatment. Furthermore, higher embryo formation rates and enhanced cleavage and blastocyst-stage embryo development were reported. After administration, 22% of women achieved a clinical pregnancy while 5% experienced natural conception.

Discussion: Intra-ovarian PRP has shown potential to improve reproductive outcomes in women with impaired ovarian function.